Blueprint Medicines Corp. (BPMC) Trading 2.7% Higher
Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) traded up 2.7% during mid-day trading on Friday . The company traded as high as $27.50 and last traded at $27.33, with a volume of 100,815 shares traded. The stock had previously closed at $26.60.
A number of analysts have issued reports on the stock. Zacks Investment Research lowered shares of Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research note on Thursday. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. Wedbush reiterated an “outperform” rating and set a $41.00 price target on shares of Blueprint Medicines Corp. in a research note on Tuesday, August 9th. Canaccord Genuity assumed coverage on shares of Blueprint Medicines Corp. in a research note on Friday, August 5th. They set a “buy” rating and a $26.00 price target on the stock. Finally, TheStreet upgraded shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research note on Friday, July 29th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $29.43.
The firm has a 50 day moving average price of $22.05 and a 200-day moving average price of $18.71. The stock’s market cap is $736.22 million.
Blueprint Medicines Corp. (NASDAQ:BPMC) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.03. During the same period in the previous year, the business posted ($0.81) earnings per share. The business earned $7.07 million during the quarter, compared to analyst estimates of $4.41 million. The firm’s quarterly revenue was up 163.0% on a year-over-year basis. Equities research analysts predict that Blueprint Medicines Corp. will post ($3.05) EPS for the current fiscal year.
In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $22.86, for a total value of $388,620.00. Following the sale, the chief executive officer now directly owns 76,494 shares of the company’s stock, valued at approximately $1,748,652.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
A hedge fund recently raised its stake in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC raised its position in Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned 2.73% of Blueprint Medicines Corp. worth $19,500,000 at the end of the most recent quarter.
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.